Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease
PHILADELPHIA--(BUSINESS WIRE)--Oct 25, 2023--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the enrollment of the first subject in its Phase 1 trial of ABX1100, AroÄ¢¹½ÊÓÆµ lead Centyrin-siRNA program for ...


